GO:0062152 mRNA (cytidine-5-)-methyltransferase activity

GO:0062152, mRNA (cytidine-5-)-methyltransferase activity, is a molecular function that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to a cytidine residue within an mRNA molecule, yielding 5-methylcytidine in mRNA, S-adenosyl-L-homocysteine, and a proton. This modification is a key component of the epitranscriptome, the collection of chemical modifications on RNA that expands the coding capacity of the genome without altering the DNA sequence. Researchers study this activity because it influences nearly every aspect of mRNA metabolism, including splicing, nuclear export, stability, and translation efficiency. The reverse reaction, demethylation, is also actively regulated, making mRNA cytidine methylation a dynamic and reversible process. The enzymatic activity defined by GO:0062152 is carried out by proteins that belong to the Rossmann-fold methyltransferase superfamily, which use S-adenosyl-L-methionine as the methyl donor. The byproduct S-adenosyl-L-homocysteine is a potent inhibitor of many methyltransferases, and its clearance is tightly linked to one-carbon metabolism, including methionine and folate cycles. Consequently, nutritional or metabolic perturbations that alter S-adenosyl-L-methionine or S-adenosyl-L-homocysteine levels can indirectly affect mRNA cytidine methylation. This connection highlights the importance of GO:0062152 in integrating cellular metabolism with post-transcriptional gene regulation. From a disease perspective, aberrant mRNA cytidine methylation has been associated with cancer, where changes in methylation patterns can lead to silencing of tumor suppressor genes or activation of oncogenes. For example, hypermethylation of promoter regions of genes such as p16INK4a, RARbeta, and MGMT can be reversed by natural compounds like genistein, suggesting that modulating methylation activity has therapeutic potential. In lymphoma, the absence of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma cells from apoptosis, illustrating how altered gene expression programs, potentially influenced by epitranscriptomic marks, contribute to cancer cell survival. Thus, understanding GO:0062152 is critical for both basic RNA biology and translational research.

GO:0062152 is defined as the catalysis of the reaction: a cytidine in mRNA + S-adenosyl-L-methionine = a 5-methylcytidine in mRNA + H+ + S-adenosyl-L-homocysteine. In simpler terms, it is the enzyme activity that adds a methyl group to cytidine bases within messenger RNA, using S-adenosyl-L-methionine as the methyl donor and producing S-adenosyl-L-homocysteine as a byproduct. This activity is synonymous with mRNA (cytosine-5-)-methyltransferase activity and represents a key epigenetic modification at the RNA level.

GO:0062152 is important because it represents a fundamental mechanism by which cells regulate gene expression post-transcriptionally. The addition of a methyl group to cytidine in mRNA can alter the secondary structure of the RNA, affect interactions with RNA-binding proteins, and influence translation efficiency and decay rates. This activity is also linked to one-carbon metabolism, as the methyl donor S-adenosyl-L-methionine and the inhibitor S-adenosyl-L-homocysteine are central metabolites in methionine and folate cycles. Dysregulation of this activity has been observed in cancer, where abnormal methylation patterns contribute to oncogenesis and can be targeted by dietary compounds such as genistein. Furthermore, in diseases like ALK-positive T-cell lymphoma, altered gene expression programs that may involve epitranscriptomic modifications affect apoptosis and cell survival. Therefore, studying GO:0062152 provides insights into both normal cellular physiology and disease pathogenesis.

The following genes encode proteins that either catalyze mRNA cytidine methylation, regulate the reaction, or serve as readers and erasers of the mark, based on published literature.

The activity of mRNA (cytidine-5-)-methyltransferase is regulated at multiple levels. First, the expression levels of the methyltransferase enzymes themselves are controlled by transcription factors and microRNAs. Second, the availability of the methyl donor S-adenosyl-L-methionine, which is influenced by one-carbon metabolism, directly affects enzyme activity. Third, the accumulation of the byproduct S-adenosyl-L-homocysteine inhibits the enzyme, so its clearance by S-adenosyl-L-homocysteine hydrolase is critical. Fourth, demethylases can remove the mark, creating a dynamic equilibrium. Finally, reader proteins can modulate the functional consequences of methylation without affecting the enzymatic rate. In cancer, aberrant expression of methyltransferases and demethylases leads to altered methylation patterns, as seen with genistein treatment reversing hypermethylation of p16INK4a, RARbeta, and MGMT. In lymphoma, the absence of TNFalpha expression protects ALK+ TCL cells from apoptosis, suggesting that cytokine signaling may influence epitranscriptomic regulation.

Dysregulated mRNA cytidine methylation is increasingly recognized in cancer. Hypermethylation of tumor suppressor gene promoters, such as p16INK4a, RARbeta, and MGMT, can be reversed by genistein and other isoflavones, indicating that methylation inhibitors may have therapeutic potential. In ALK-positive T-cell lymphoma, the lack of TNFalpha expression protects cells from apoptosis, highlighting how altered gene expression programs contribute to cancer cell survival. These findings suggest that targeting GO:0062152 activity or its regulatory network could be a strategy for cancer therapy.

Because mRNA cytidine methylation depends on S-adenosyl-L-methionine and is inhibited by S-adenosyl-L-homocysteine, conditions that alter one-carbon metabolism can impact this activity. In neonatal Holstein dairy calves, maternal methionine supply during late pregnancy altered hepatic one-carbon metabolism enzyme activity and intermediate metabolites, which may affect global methylation capacity. This illustrates how nutritional and metabolic status can influence epitranscriptomic marks, with potential implications for growth and development.

Mutations in NSUN2, a major mRNA cytidine methyltransferase, have been linked to intellectual disability and neurodevelopmental disorders. Although the exact mechanisms are still being elucidated, the loss of NSUN2 function leads to reduced 5-methylcytidine in mRNA, affecting the translation of genes critical for neuronal development. This underscores the importance of GO:0062152 in normal brain function and disease.

MeRIP-seq uses an antibody specific to 5-methylcytidine to immunoprecipitate methylated RNA fragments, followed by next-generation sequencing. This method allows transcriptome-wide mapping of cytidine methylation sites at single-nucleotide resolution. It is widely used to identify targets of GO:0062152 and to compare methylation patterns between conditions, such as genistein treatment.

Bisulfite treatment converts unmethylated cytidine to uracil while methylated cytidine remains unchanged. After reverse transcription and sequencing, methylated sites are detected as cytidine reads. This technique provides quantitative and stoichiometric information about mRNA cytidine methylation, complementing antibody-based methods.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can directly quantify 5-methylcytidine levels in purified mRNA. This approach is highly sensitive and can detect global changes in methylation stoichiometry. It is often used to validate findings from sequencing-based methods and to measure enzyme activity in vitro.

CRISPR-Cas9 knockout, knock-in, and point-mutation models enable causal testing of candidate genes in mRNA cytidine methylation. For example, knocking out NSUN2 abolishes specific methylation marks, while point mutations in the catalytic domain can separate enzymatic activity from other functions. These models are essential for linking genotype to epitranscriptomic phenotype.

Researchers studying mRNA (cytidine-5-)-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in the deposition, recognition, or removal of 5-methylcytidine in mRNA. Establishing causality requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from custom knockout cell lines to library screening and bioinformatics analysis.

GO:0062152, mRNA (cytidine-5-)-methyltransferase activity, is a central enzymatic function in the epitranscriptomic regulation of gene expression. It controls the deposition of 5-methylcytidine in mRNA, influencing transcript fate and cellular physiology. Dysregulation of this activity contributes to cancer, metabolic disorders, and neurodevelopmental diseases, making it an attractive target for therapeutic intervention. Advances in CRISPR-based models and sequencing technologies continue to unravel the complex regulatory networks surrounding this modification. EDITGENE offers a full range of services to support research on this critical activity.